promazine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2284 58-40-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • promazine
  • prazin
  • prazine
  • romtiazin
  • promazine hydrochloride
  • promazine HCl
A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.
  • Molecular weight: 284.42
  • Formula: C17H20N2S
  • CLOGP: 4.60
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.14
  • ROTB: 4

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 333.33 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 50.23 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 16.25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 8.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.11 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 13, 1956 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 561.20 54.89 128 1438 19751 50583807
Drug abuse 232.76 54.89 82 1484 59764 50543794
Intentional self-injury 114.13 54.89 38 1528 23074 50580484
Electrocardiogram QT prolonged 100.53 54.89 43 1523 51843 50551715
Intentional overdose 92.84 54.89 43 1523 62461 50541097
Drug interaction 65.64 54.89 52 1514 199569 50403989
Alcohol interaction 61.06 54.89 14 1552 2130 50601428
Coma 59.96 54.89 31 1535 56848 50546710
Overdose 58.37 54.89 37 1529 99690 50503868

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 262.70 46.81 68 1398 10866 29562195
Intentional self-injury 127.98 46.81 40 1426 12421 29560640
Drug abuse 124.98 46.81 66 1400 79817 29493244
Suicide attempt 121.84 46.81 50 1416 34060 29539001
Intentional overdose 96.56 46.81 44 1422 38484 29534577
Somnolence 76.46 46.81 51 1415 93904 29479157
Drug interaction 50.45 46.81 55 1411 197330 29375731

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 794.92 42.00 199 2852 29462 64466219
Drug abuse 326.49 42.00 147 2904 132227 64363454
Intentional self-injury 239.39 42.00 78 2973 28966 64466715
Electrocardiogram QT prolonged 124.66 42.00 65 2986 79383 64416298
Intentional overdose 122.60 42.00 67 2984 89877 64405804
Drug interaction 103.81 42.00 105 2946 361978 64133703
Suicide attempt 102.56 42.00 55 2996 70952 64424729
Alcohol interaction 80.82 42.00 22 3029 4379 64491302
Coma 74.03 42.00 48 3003 87567 64408114
Bradyphrenia 72.25 42.00 24 3027 9382 64486299
Intentional product misuse 69.54 42.00 43 3008 72252 64423429
Overdose 62.15 42.00 55 2996 159511 64336170
Hypotension 57.90 42.00 80 2971 380894 64114787
Somnolence 52.56 42.00 56 2995 203589 64292092
Inappropriate antidiuretic hormone secretion 52.14 42.00 24 3027 22265 64473416
Neuroleptic malignant syndrome 49.52 42.00 24 3027 24972 64470709
Bradypnoea 42.97 42.00 14 3037 5145 64490536

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AA03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain
MeSH PA D000932 Antiemetics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Nausea and vomiting indication 16932000
Angioedema indication 41291007 DOID:1558
General anesthesia indication 50697003
Disruptive behavior disorder indication 54319003
Schizophrenia indication 58214004 DOID:5419
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Psychotic disorder indication 69322001
Sneezing indication 76067001
Urticaria indication 126485001
Bipolar affective disorder, current episode manic indication 191618007
Acute intermittent porphyria indication 234422006 DOID:3890
Itching of skin indication 418363000
Vomiting indication 422400008
Nausea indication 422587007
Allergic conjunctivitis indication 473460002 DOID:11204
Pre-Op Apprehension indication
Tetanus Adjunct Treatment indication
Intractable Hiccups indication
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

ProductApplicantIngredients
Promazine HCl Injectable Zoetis Inc. 1
Promazine Granules Zoetis Inc. 1
Ketaset Plus Zoetis Inc. 3
Tranquazine Injection Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 3.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 6.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.80 WOMBAT-PK CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.94 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 7.34 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 7.89 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.53 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.66 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.28 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.90 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR Ki 8.23 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.50 WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 6.80 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.70 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.55 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.83 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 6.41 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.06 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.38 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.34 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.80 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.43 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.52 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 8.43 DRUG MATRIX
Major prion protein Surface antigen EC50 5.30 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.76 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.27 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.91 DRUG MATRIX
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.89 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.90 DRUG MATRIX
Trypanothione reductase Enzyme Ki 4.23 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 8.34 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.81 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 8.03 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.29 CHEMBL
Histamine H1 receptor GPCR IC50 5.90 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 4.95 CHEMBL
Dopamine receptor GPCR IC50 6.89 CHEMBL
Dopamine receptor GPCR IC50 5.98 CHEMBL

External reference:

IDSource
4019909 VUID
N0000147994 NUI
D00797 KEGG_DRUG
53-60-1 SECONDARY_CAS_RN
4018021 VANDF
4019909 VANDF
C0033399 UMLSCUI
CHEBI:8459 CHEBI
P2Z PDB_CHEM_ID
CHEMBL564 ChEMBL_ID
CHEMBL1200469 ChEMBL_ID
DB00420 DRUGBANK_ID
D011395 MESH_DESCRIPTOR_UI
4926 PUBCHEM_CID
7281 IUPHAR_LIGAND_ID
600 INN_ID
O9M39HTM5W UNII
142444 RXNORM
2128 MMSL
5366 MMSL
7219 MMSL
d00356 MMSL
001471 NDDF
004588 NDDF
372741002 SNOMEDCT_US
44658005 SNOMEDCT_US
79135001 SNOMEDCT_US

Pharmaceutical products:

None